Abstract: Disclosed are diagnostics for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.

Abstract: The present invention relates to methods of inhibiting neurodegeneration in a subject suffering from or genetically at risk and/or destined to develop Huntington's Disease comprising increasing, in neurons of the subject, the activity of the TIM23 mitochondrial protein import complex.

Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.

Abstract: Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the like.

Abstract: The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.

Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using amyloid precursor protein (APP)-derived A? and A?-like peptides in a living body-derived sample as an index, and a method for analysis thereof. A marker for determining a cerebral A? accumulation state, the marker comprising a combination of at least two ratios selected from the group consisting of: a ratio of A?1-39 (SEQ ID NO.: 1) level to A?1-42 (SEQ ID NO.: 3) level: A?1-39/A?1-42; a ratio of A?1-40 (SEQ ID NO.: 2) level to A?1-42 (SEQ ID NO.: 3) level: A?1-40/A?1-42; and a ratio of APP669-711 (SEQ ID NO.: 4) level to A?1-42 (SEQ ID NO.: 3) level: APP669-711/A?1-42, in a living body-derived sample.

Abstract: Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin ?4?1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Abstract: An immunoassay kit including a monoclonal antibody coupled to a labeling agent (labeled mAb) for detecting tumor pyruvate kinase M2 (tM2-PK) in a biological sample. The monoclonal antibody includes a heavy chain variable region (HCVR) including heavy chain complementarity-determining regions (CDRs) (SEQ ID NOs: 3, 4, and 5) and a light chain variable region (LCVR) including light CDRs (SEQ ID NOs: 7, 8, and 9).

Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.

Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.

Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.

Abstract: The subject invention provides methods of treating neurological disease or disorder, such as brain injuries, such as stroke, traumatic brain injury (TBI), or other ischemic events that cause brain injury by inhibiting or down-regulating Let-7i activity or function. The disclosed methods may have the potential to extend the “window of opportunity” for treatment of such injuries and enhance the effectiveness of existing therapeutics.

Abstract: The invention relates to compositions and methods for monitoring phagocytic activity (e.g., diseases and conditions relating to phagocytic activity). In particular, the invention relates to compositions and methods for diagnosing, monitoring, and/or assessing risk of neurodegenerative diseases (e.g., AD).

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.